Insider Selling: Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Sells $16,991.51 in Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Ra Capital Management, L.P. sold 45,923 shares of the company’s stock in a transaction on Wednesday, June 10th. The shares were sold at an average price of $0.37, for a total value of $16,991.51. Following the completion of the transaction, the insider directly owned 378,666 shares in the company, valued at $140,106.42. This represents a 10.82% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Thursday, June 11th, Ra Capital Management, L.P. sold 262,503 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.38, for a total value of $99,751.14.
• On Tuesday, June 9th, Ra Capital Management, L.P. sold 369,800 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.37, for a total value of $136,826.00.
• On Tuesday, May 12th, Ra Capital Management, L.P. sold 101,151 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.64, for a total value of $64,736.64.
• On Monday, May 11th, Ra Capital Management, L.P. sold 87,490 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.67, for a total value of $58,618.30.
• On Friday, May 8th, Ra Capital Management, L.P. sold 376,526 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.71, for a total value of $267,333.46.

Werewolf Therapeutics Trading Down 3.3%

Shares of HOWL opened at $0.38 on Friday. The business’s 50-day moving average price is $0.66 and its 200 day moving average price is $0.71. The stock has a market capitalization of $18.52 million, a P/E ratio of -0.31 and a beta of 0.29. Werewolf Therapeutics, Inc. has a 1-year low of $0.36 and a 1-year high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.04. On average, research analysts predict that Werewolf Therapeutics, Inc. will post -1.08 earnings per share for the current year.

Institutional Investors Weigh In On Werewolf Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HOWL. Regal Investment Advisors LLC increased its stake in shares of Werewolf Therapeutics by 93.3% in the fourth quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock worth $33,000 after acquiring an additional 25,389 shares during the last quarter. Vontobel Holding Ltd. boosted its position in Werewolf Therapeutics by 66.7% during the fourth quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock valued at $38,000 after purchasing an additional 24,003 shares during the last quarter. Qube Research & Technologies Ltd purchased a new position in Werewolf Therapeutics in the second quarter valued at about $48,000. AQR Capital Management LLC purchased a new position in Werewolf Therapeutics in the first quarter valued at about $79,000. Finally, Bridgeway Capital Management LLC increased its position in Werewolf Therapeutics by 157.7% in the 2nd quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock worth $111,000 after purchasing an additional 62,414 shares during the last quarter. Hedge funds and other institutional investors own 64.84% of the company’s stock.

Analysts Set New Price Targets

HOWL has been the subject of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Monday, April 20th. Wall Street Zen cut Werewolf Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Two research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Werewolf Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $3.75.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.